Back to top

Barclays Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)

In a report released today, Eliana Merle from Barclays maintained a Buy rating on Alnylam Pharma, with a price target of $527.00. According to TipR...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Alnylam Pharmaceuticals, Inc. (ALNY)